TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12749389

Group type: EXPERIMENTAL
Intervention: 3D active-surface border detection system
Number of subjects: 9

Group type: COMPARATOR
Intervention: Manual tracing by four experienced observers
Number of subjects: 9
Study: 10533344

Group type: EXPERIMENTAL
Intervention: Documentation-and-payment group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Documentation-only group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Silent control group
Number of subjects: 200
Study: 8690121

Group type: EXPERIMENTAL
Intervention: GH + hCG protocol: 4 IU SC GH daily 8 days before and throughout the hCG phase
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: plain hCG protocol: 1,500 IU IM three times every other day
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo + hCG: substitution of GH by NaCL 0.9%
Number of subjects: 8
Study: 1911739

Group type: EXPERIMENTAL
Intervention: CCK‐4 9 micrograms
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CCK‐4 25 micrograms
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CCK‐4 50 micrograms
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 6791938

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment (25 mg x 4 daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 22

Group type: COMPARATOR
Intervention: Alcohol addicts with diarrhoea or steatorrhoea
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patients with chronic diarrhoea
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patients with intermittent diarrhoea classified as irritable bowel syndrome
Number of subjects: 22
Study: 31725142

Group type: EXPERIMENTAL
Intervention: 1 g intravenous (IV) tranexamic acid given 1 to 3 hours after delivery
Number of subjects: 0
Study: 28250047

Group type: EXPERIMENTAL
Intervention: Job rotation programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (ergonomic training only)
Number of subjects: 0
Study: 26340264

Group type: EXPERIMENTAL
Intervention: DHA plus EPA (2 g/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23657962

Group type: EXPERIMENTAL
Intervention: Olmesartan + Amlodipine (fixed combination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of Olmesartan + Amlodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Separate administration of Olmesartan + Amlodipine
Number of subjects: 0
Study: 21418836

Group type: EXPERIMENTAL
Intervention: Combined treatment group
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study: 19920423

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electrical stimulation (ES) guidance
Number of subjects: 40
Study: 16963038

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard insemination (IVF)
Number of subjects: 95
Study: 16279219

Group type: EXPERIMENTAL
Intervention: Acupuncture (verum group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (verum and placebo)
Number of subjects: 0
Study: 11256536

Group type: EXPERIMENTAL
Intervention: ACE-inhibitor therapy
Number of subjects: 0
Study: 8988997

Group type: EXPERIMENTAL
Intervention: Cocaine 0.50 mg/kg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study: 8501270

Group type: EXPERIMENTAL
Intervention: Irrigator with a magnetic device
Number of subjects: 54

Group type: COMPARATOR
Intervention: Unmagnetized irrigator (Control)
Number of subjects: 54
Study: 3326689

Group type: EXPERIMENTAL
Intervention: Bay‐m‐1099 (50 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bay‐o‐1248 (20 mg or 10 mg)
Number of subjects: 31
Study: 29327085

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Education/Support (Control)
Number of subjects: 47
Study: 26707493

Group type: EXPERIMENTAL
Intervention: Universal parent training
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 151
Study: 25581660

Group type: EXPERIMENTAL
Intervention: Drinking-reduction intervention
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: HIV/HCV coinfected patients
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Effort to restrict drinking
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Awareness of medical risk
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Reported effort to restrict drinking
Number of subjects: 254
Study: 22840988

Group type: EXPERIMENTAL
Intervention: Autogenous hamstring tendon
Number of subjects: 147

Group type: COMPARATOR
Intervention: Fresh-frozen allograft anterior tibialis tendon
Number of subjects: 147
Study: 20423998

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg twice daily p.o. for a minimum of 14 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (not receiving a Cox inhibitor)
Number of subjects: 13
Study: 17161126

Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interviewing (ACASI)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Face-to-face (FTF) interview
Number of subjects: 655
Study: 15370247

Group type: COMPARATOR
Intervention: Chlorambucil 0.1 mg/kg/day indefinitely
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Chlorambucil 0.1 mg/kg/day plus theophylline 200 mg bid, orally
Number of subjects: 210
Study: 11292522

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 9034682

Group type: EXPERIMENTAL
Intervention: Water-based metalworking fluids (MWF) applied with Finn Chambers for 1 day, then reapplied for 2 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative irritant contact dermatitis induced using a repetitive irritation test for 2 weeks (6 hours per day, omitting weekends)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D1/D3 model as a predictive test of MWF irritancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidemiological data correlation
Number of subjects: 0
Study: 7911011

Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl glutamic acid (NAAGA) (Rhinaaxia)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 230
Study: 3330527

Group type: EXPERIMENTAL
Intervention: Alinidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study: 30524135

Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) analysis
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: Recall-by-Genotype (RbG) analysis
Number of subjects: 3108

Group type: EXPERIMENTAL
Intervention: RbG analysis
Number of subjects: 3108
Study: 27566117

Group type: EXPERIMENTAL
Intervention: Collaborative Life Skills (CLS)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 135
Study: 24322182

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/vitamin D₃ 1000 IU daily
Number of subjects: 518

Group type: COMPARATOR
Intervention: Strontium ranelate 2 g daily
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 518
Study: 21939611

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (olanzapine, risperidone, quetiapine)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 20137765

Group type: EXPERIMENTAL
Intervention: Insulin glargine (IG, Lantus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin detemir (ID, Levemir)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin glargine (IG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin detemir (ID)
Number of subjects: 0
Study: 17609679

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 124

Group type: COMPARATOR
Intervention: First-generation antipsychotics (FGAs)
Number of subjects: 124
Study: 16029567

Group type: COMPARATOR
Intervention: Propofol 2.5 mg/kg intravenous injection
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 microg intravaginally
Number of subjects: 200
Study: 15273525

Group type: EXPERIMENTAL
Intervention: Rehabilitation program (12 sessions over 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 20
Study: 11374267

Group type: EXPERIMENTAL
Intervention: Instructions for shoulder, elbow, and finger exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 30
Study: 9150838

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inhaled amiloride
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7524885

Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal adults
Number of subjects: 0
Study: 3586818

Group type: EXPERIMENTAL
Intervention: Swimming without earplugs
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Swimming with earplugs
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: No swimming
Number of subjects: 85
Study: 30633595

Group type: EXPERIMENTAL
Intervention: LP loaded SLMs with SRP
Number of subjects: 16

Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 16
Study: 28860128

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 μg/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 26817183

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A split injection sites
Number of subjects: 31

Group type: COMPARATOR
Intervention: Botulinum toxin A non-split injection sites
Number of subjects: 31
Study: 23241943

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Clinician-rated severity
Number of subjects: 738
Study: 21153533

Group type: EXPERIMENTAL
Intervention: Weaning to a highly hydrolysed formula for 6 to 8 months
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Standard cow's milk formula
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Overall retention rate
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Protocol compliance
Number of subjects: 2160
Study: 18082499

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 258
Study: 16481083

Group type: EXPERIMENTAL
Intervention: Acute alcohol intoxication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sober participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instructional cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge about the experimental purpose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study: 14564379

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure delivered by head helmet (CPAPH)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous positive airway pressure delivered by face mask (CPAPM)
Number of subjects: 8
Study: 10629515

Group type: EXPERIMENTAL
Intervention: Sandblasted with 50 mu aluminum oxide by a microetcher
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acid etched with 37% phosphoric acid for 15 seconds
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Polished with pumice followed by acid etched with 37% phosphoric acid for 15 seconds
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sandblasted with 50 mu aluminum oxide by a microetcher followed by acid etched with 37% phosphoric acid for 15 seconds
Number of subjects: 80
Study: 9106936

Group type: EXPERIMENTAL
Intervention: 1 mg/kg anti-TNF-alpha moab
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg/kg anti-TNF-alpha moab
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1337012

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 3885891

Group type: EXPERIMENTAL
Intervention: Medically supervised exercise program (N = 28)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual community care (N = 25)
Number of subjects: 53
Study: 31235394

Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Number of subjects: 174

Group type: COMPARATOR
Intervention: No Question Prompt List (Control)
Number of subjects: 174
Study: 28689056

Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 340

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 340
Study: 26108005

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Multiple resistance
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant strains
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Levofloxacin (MIC values)
Number of subjects: 98
Study: 23953410

Group type: EXPERIMENTAL
Intervention: Experimental arm (40Gy to PTVelect)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard arm (50Gy to PTVelect)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 200
Study: 21196078

Group type: EXPERIMENTAL
Intervention: Heterotopic noxious conditioning stimulation (HNCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone (opioid antagonist)
Number of subjects: 0
Study: 19216705

Group type: EXPERIMENTAL
Intervention: Bepotastine 10 mg OD tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17923938

Group type: EXPERIMENTAL
Intervention: Gpre+intra (preoperative and intraoperative active warming)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gintra (only warmed intraoperatively)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gcontrol (preoperative and intraoperative passive thermal insulation)
Number of subjects: 30
Study: 15010083

Group type: EXPERIMENTAL
Intervention: Bilateral STN stimulation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (matched PD controls)
Number of subjects: 17
Study: 11583747

Group type: EXPERIMENTAL
Intervention: Invasive therapy (revascularisation)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 305
Study: 9634048

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 104
Study: 7889892

Group type: EXPERIMENTAL
Intervention: Fish oil (rich in n-3 fatty acids)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mixed oil (rich in saturated fatty acids)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Corn oil (rich in n-6 fatty acids)
Number of subjects: 12
Study: 3284400

Group type: EXPERIMENTAL
Intervention: Fentanyl transdermal patches (F-TTS) 75 micrograms/h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl transdermal patches (F-TTS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl transdermal patches (F-TTS) and Placebo
Number of subjects: 40
Study: 31343521

Group type: EXPERIMENTAL
Intervention: HIIT performed thrice weekly (HIIT×3/wk)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: HIIT performed twice weekly (HIIT×2/wk)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: HIIT performed once weekly (HIIT×1/wk)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: MICT performed thrice weekly (MICT×3/wk)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No-intervention control (CON)
Number of subjects: 56
Study: 27796041

Group type: EXPERIMENTAL
Intervention: Rocuronium-sugammadex (R-S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Succinylcholine-cisatracurium-pyridostigmine (S-C-P)
Number of subjects: 0
Study: 24682383

Group type: EXPERIMENTAL
Intervention: Asthma education program (three educational sessions)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 74
Study: 22531622

Group type: EXPERIMENTAL
Intervention: Compression Garment (CG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No Compression Garment (No CG)
Number of subjects: 24
Study: 21322021

Group type: EXPERIMENTAL
Intervention: Rotigotine (2-16 mg/24 hr)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 19818700

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Acute painful edematous stage treatment (surgery or conservative)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Operated group
Number of subjects: 59
Study: 17268412

Group type: EXPERIMENTAL
Intervention: Pre-dosing with 5 x 100 mg LU
Number of subjects: 15

Group type: COMPARATOR
Intervention: Without pre-dosing
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: One week after pre-dosing
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Three weeks after pre-dosing
Number of subjects: 15
Study: 15269081

Group type: EXPERIMENTAL
Intervention: Replaced UCP group (UCP replaced every 30 minutes)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single UCP group (same UCP kept in the nappy until urine was passed)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups used a moisture sensitive audio alarm
Number of subjects: 80
Study: 12745177

Group type: EXPERIMENTAL
Intervention: Salaried GP practices
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard contract GP practices
Number of subjects: 20
Study: 10594416

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1%
Number of subjects: 54

Group type: COMPARATOR
Intervention: Bupivacaine 0.75% and Lignocaine 2%
Number of subjects: 54
Study: 7560253

Group type: EXPERIMENTAL
Intervention: 200 mg DHCl
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 80 mg PHCl
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 200 mg DHCl and 80 mg PHCl
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 9
Study: 2090337

Group type: EXPERIMENTAL
Intervention: 2.5% topical ocular phenylephrine hydrochloride
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 5% topical ocular phenylephrine hydrochloride
Number of subjects: 200
Study: 40376

Group type: EXPERIMENTAL
Intervention: Dixyrazine (Esucos)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 321

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 321
Study: 31711312

Group type: EXPERIMENTAL
Intervention: Naturalistic listening in real time (NLRT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Phonetic transcription
Number of subjects: 33
Study: 31318615

Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation (0.1 mmol·kg‐1·day ‐1) for 7 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study: 28639995

Group type: EXPERIMENTAL
Intervention: TDF/FTC (Truvada) adherence
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study: 26787691

Group type: EXPERIMENTAL
Intervention: Dried Blood Spot (DBS) sampling method for miltefosine quantification
Number of subjects: 16
Study: 24182735

Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: No EMG biofeedback
Number of subjects: 30
Study: 22449646

Group type: EXPERIMENTAL
Intervention: Medication switch
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Medication switch plus CBT
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Anhedonia and CDRS-total score evaluated simultaneously
Number of subjects: 334
Study: 19411105

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 44
Study: 16958130

Group type: EXPERIMENTAL
Intervention: Continuous dopaminergic stimulation (CDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa therapy
Number of subjects: 0
Study: 15871756

Group type: EXPERIMENTAL
Intervention: Intermittent Positive Expiratory Pressure (PEP) therapy, n = 11
Number of subjects: 20

Group type: COMPARATOR
Intervention: Incentive Spirometry (IS), n = 9
Number of subjects: 20
Study: 12477218

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (24 microg bid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 microg b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9536878

Group type: EXPERIMENTAL
Intervention: 2% carteolol with benzalkonium chloride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% carteolol without benzalkonium chloride (preservative free)
Number of subjects: 30
Study: 7634183

Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 42

Group type: COMPARATOR
Intervention: FSH
Number of subjects: 42
Study: 29094366

Group type: EXPERIMENTAL
Intervention: Bio Skin Oil® applied for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control untreated area
Number of subjects: 80
Study: 26577258

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (11 patients)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard treatment (10 patients)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Exercise myocardial perfusion SPECT
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Baseline to 1 month comparison
Number of subjects: 21
Study: 25171033

Group type: EXPERIMENTAL
Intervention: Grafted and covered with a membrane (test group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 52
Study: 23739063

Group type: EXPERIMENTAL
Intervention: Trastuzumab (9 weeks)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: No trastuzumab
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: PIK3CA mutations
Number of subjects: 1010